A 58-year-old male smoker presents with a 3-month history of cough, chest pain, and weight loss. Imaging reveals a central lung mass with mediastinal lymphadenopathy. Bronchoscopic biopsy confirms small cell lung cancer (SCLC) with extensive stage disease. Which is the drug of choice for first-line chemotherapy in this patient?

Question

Accepted Answer

B. Cisplatin + Etoposide. ## First-Line Chemotherapy for Small Cell Lung Cancer

**Key Point:** Cisplatin + Etoposide (PE) is the gold-standard first-line regimen for both limited-stage and extensive-stage SCLC, established by decades of clinical trials and endorsed by all major guidelines.

### Mechanism of Action
- **Cisplatin:** Platinum-based alkylating agent; forms DNA cross-links → apoptosis
- **Etoposide:** Topoisomerase II inhibitor; prevents DNA unwinding → strand breaks

### Why PE is Superior in SCLC

| Feature | Cisplatin + Etoposide | Carboplatin + Pemetrexed | Docetaxel + Cisplatin |
|---------|----------------------|--------------------------|------------------------|
| **SCLC efficacy** | Gold standard (ORR 60–80%) | Non-SCLC agent (adenocarcinoma) | Inferior in SCLC |
| **Toxicity profile** | Manageable with hydration | Myelosuppression, renal | Peripheral neuropathy |
| **Evidence base** | Level 1A (multiple RCTs) | Level 3 (NSCLC trials) | Level 3 (NSCLC trials) |
| **Guideline recommendation** | NCCN, ESMO, ASCO | Not recommended for SCLC | Not recommended for SCLC |

**High-Yield:** SCLC is exquisitely chemosensitive — PE achieves response rates of 60–80% in extensive-stage disease, but median overall survival remains 10–12 months without maintenance therapy or immunotherapy.

### Dosing Schedule
- Cisplatin 75 mg/m² IV day 1 + Etoposide 100 mg/m² IV days 1–3
- Repeated every 3 weeks for 4–6 cycles
- Hydration and antiemetics mandatory

**Clinical Pearl:** Carboplatin may substitute for cisplatin in patients with renal impairment or hearing loss, but pemetrexed is a non-small-cell agent and is not indicated for SCLC.

**Warning:** Pemetrexed is specifically designed for non-squamous NSCLC and adenocarcinoma; using it in SCLC represents a fundamental misunderstanding of lung cancer histology-directed therapy.

### Modern Additions (Post-First-Line)
- Atezolizumab (PD-L1 inhibitor) added to PE in extensive-stage SCLC improves OS (IMpower133 trial)
- However, the chemotherapy backbone remains PE

[cite:Harrison 21e Ch 105]

Answer

A. Gemcitabine + Vinorelbine

Answer

C. Carboplatin + Pemetrexed

Answer

D. Docetaxel + Cisplatin

Explanation

First-Line Chemotherapy for Small Cell Lung Cancer

Mechanism of Action

Why PE is Superior in SCLC

Dosing Schedule

Modern Additions (Post-First-Line)

Practice similar questions

Join our NEET PG community

Feature	Cisplatin + Etoposide	Carboplatin + Pemetrexed	Docetaxel + Cisplatin
SCLC efficacy	Gold standard (ORR 60–80%)	Non-SCLC agent (adenocarcinoma)	Inferior in SCLC
Toxicity profile	Manageable with hydration	Myelosuppression, renal	Peripheral neuropathy
Evidence base	Level 1A (multiple RCTs)	Level 3 (NSCLC trials)	Level 3 (NSCLC trials)
Guideline recommendation	NCCN, ESMO, ASCO	Not recommended for SCLC	Not recommended for SCLC